A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
A phase 1/2 trial of Prednisone, Dexamethasone and Lenvatinib in advanced solid tumours, run by Eisai Inc., now recruiting.
Overview
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types is a phase 1/2 interventional study registered as NCT04300556 by Eisai Inc., with 182 participants planned, started 2020-08-06 and due to reach its primary completion in 2030-08-08. Interventions recorded: Farletuzumab ecteribulin, Prednisone, Prednisolone, Dexamethasone and Lenvatinib.
Similar pages
not linked directly; found by shared links- TrialA Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Shares Eisai, Lenvatinib and the tag pipeline.
- TrialA Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
Shares Eisai, Lenvatinib and the tag pipeline.
- TrialA Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Shares Eisai, Lenvatinib and the tag pipeline.
- TrialA Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
Shares Eisai, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Shares Lenvatinib, Dexamethasone and the tag pipeline.
- TrialPembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Shares Lenvatinib, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Shares Lenvatinib, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialExtension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Shares Lenvatinib, Metastatic cancer (cancer that has spread) and the tag pipeline.